

Welcome to California COVID-19 Vaccination Program Friday Provider Office Hours

Friday, July 1, 2022




Vaccinate ALL 58

Together we can end the pandemic.

Provider Office Hours Q&A

During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.



Housekeeping

Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:



Today's session is being recorded. Access today's slides and archived presentations at:
<https://eziz.org/covid/education/>



If you have post-webinar questions, please email leslie.amani@cdph.ca.gov


Agenda: Friday, July 1, 2022

No.	Item	Speaker	Time (AM)
1	Welcome & Announcements	Leslie Amani (Moderator)	9:00 – 9:05
2	KidsVaxGrant	Thomas Villagomez (CDPH)	9:05 – 9:10
3	Vaccine Administration Data	Elizabeth Reosti (CDPH)	9:10 – 9:15
4	Clinical Update	Floria Chi, MD (CDPH)	9:15 – 9:25
Q&A			9:25 – 9:30
5	Storage & Handling	Kate McHugh (CDPH)	9:30 – 9:35
6	Vaccine Management	Eric Norton (My Turn) and Maria Volk (CDPH)	9:35 – 9:45
7	Wrap Up & Resources	Leslie Amani (Moderator)	9:45 – 10:00
Q&A			

Announcements

Leslie Amani, CDPH

CDPH: Close Contact & Masking Guidance



Letter from Dr. Aragón


Added definitions for close contact and infectious period.



California: Full Masking Guidance

Get the Most Out of Masking

Job Aid: Preparing for Infant/Toddler Vaccinations



Vaccinate ALL 58

Preparing for Infant/Toddler Vaccinations

Whenever new vaccine products are introduced into your practice's supply, ensure staff are properly trained on what's new and reinforce the storage and handling basics staff already know. This guide addresses training issues and setup required to support new pediatric vaccine products.

#1. Review Clinical, Safety, and Efficacy Talking Points

We'll share findings from the clinical trials once data are available. In the meantime, [review clinical talking points for parents](#) and start talking to families about COVID-19 vaccines now!

#2. Complete the COVID-19 Product Training

CDC's training for any new vaccine products will be posted [here](#) once released by CDC. In the meantime, review FDA's EUA Fact Sheets for each product you'll administer.

To ensure everyone is proficient with any new products in your inventory, CDC requires that everyone storing, handling, administering, or managing COVID-19 vaccines complete the [COVID-19 Vaccine Product Training](#).

CDC training is broken down into separate *Preparation & Administration* and *Storage & Handling* summaries so staff and clinicians can review the training appropriate to their roles and print them for reference.

Bookmark the [COVID-19 Vaccine Product Guide](#) as a quick reference.

#3. Review Timing for Doses by Age

Ensure staff know how to identify which vaccine is for which age group. [This chart](#) includes two schedules (routine and for moderately and severely immunocompromised) for primary and booster doses.

California COVID-19 Vaccination Program


IMM-1432 (6/17/22)

Product Updates

CDC and the California Department of Public Health are updating job aids and communications for the following product authorizations:

- Pfizer-BioNTech COVID-19 boosters for children 5-11Y ([recommended](#))
- Pfizer-BioNTech COVID-19 primary vaccine series for 6M-4Y ([Fact Sheet](#))
- Moderna COVID-19 primary vaccine series doses for 12Y+, boosters for 18Y+ ([Fact Sheet updated](#))
- Moderna COVID-19 primary vaccine series for 6M-5Y ([Fact Sheet](#))
- Moderna COVID-19 primary vaccine series for 6-11Y ([Fact Sheet](#))

COVID Call Center will keep sites posted as new pediatric products or boosters are authorized by FDA and recommended by the Advisory Committee on Immunization Practices (ACIP), CDC, and Western States Scientific Safety Review Workgroup (WSSSRW).



Includes:

- Safety and Efficacy
- Product Training
- Timing for Doses
- Vaccine Organization
- Preparing Staff
- Links to Resources



Moderna COVID-19 Vaccine Job Aids

6 Through 11 Years of Age
Moderna COVID-19 Vaccine
Updated Label Information

703595

STORE FROZEN between -50° to -15°C (-58° to 5°F). Protect from light. No preservative. After first use, hold at 2° to 25°C (36° to 77°F). Discard after 12 hours. Record date/time of first use: _____

Scan here for FDA-authorized Fact Sheet for dosage and administration, and product expiration dates, or visit www.modernatx.com/covid19vaccine-eua/
Mfd. for: Moderna US, Inc., Cambridge, MA 02139

Moderna COVID-19 Vaccine
Suspension for Intramuscular Injection
For use under Emergency Use Authorization
BOOSTER DOSES ONLY
2.5 mL Multi-Dose Vial
Booster Dose: 0.5 mL

NDC 80777-275-05
LOT

Labeled for “BOOSTER DOSES ONLY” but is authorized for:

- Primary doses in children ages 6–11 years
- Booster doses in adults ages 18 years and older

06/23/2022 CS201571.F

1

Moderna COVID-19 Vaccine At-A-Glance
Ages 6 months and older

The tables below summarize basic storage, preparation, scheduling, administration, and dosage for Moderna COVID-19 Vaccine.

EUA Fact Sheet
www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine

CDC Interim Clinical Considerations
www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

CDC Clinical Materials
www.cdc.gov/vaccines/covid-19/info-by-product/moderna

Interim COVID-19 Vaccination Schedule
<https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf>

Storage and Handling Basics
NOTE: Find additional guidance on storing the vaccine properly at:
• CDC’s COVID-19 Clinical materials for Moderna COVID-19 Vaccine: www.cdc.gov/vaccines/covid-19/info-by-product/moderna/storage.html
• CDC’s Storage and Handling Toolkit: www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf

Vial cap color	Blue vial cap with magenta bordered label	Blue vial cap with purple bordered label	Red vial cap with blue bordered label
Ages	6 months through 5 years	6 years through 11 years	12 years and older
Supplied in multidose vial	10 doses per vial	5 doses per vial	Per vial: <ul style="list-style-type: none">10 primary doses (0.5 mL) or20 booster doses (0.25 mL)20 doses: Combination of primary series and booster doses Discard vial and any remaining vaccine after 20 punctures.
Storage Temperature: Before Puncture	Between: -50°C and -15°C (-58°F and 5°F) until the expiration date 2°C and 8°C (36°F and 46°F) for up to 30 days 8°C and 25°C (46°F and 77°F) for a total of 24 hours. Discard vial and unused vaccine after 24 hours.		
Thawing Frozen Vaccine	Between: 2°C and 8°C (36°F and 46°F) for 2 hours. Let each vial stand at room temperature for 15 minutes before administering. Do NOT refreeze thawed vaccine. OR 15°C and 25°C (46°F and 77°F) for 45 minutes.		
Storage Temperature: After Puncture	Between: 2°C and 25°C (36°F and 77°F) for up to 12 hours. Discard vial and any unused vaccine after 12 hours.		

06/24/2022 CS201571.F

1

2

3



Pfizer COVID-19 Vaccine Job Aids

6 Months Through 4 Years of Age
Pfizer-BioNTech COVID-19 Vaccine
Updated Label Information

Vial label states Age 2y to <5y
BUT can be used for children
ages 6 months through 4 years.

LOT/MFG
PAA178296

Pfizer-BioNTech COVID-19 Vaccine
DILUTE PRIOR TO USE Age 2y to <5y
After dilution - 10 doses of 0.2 mL
For intramuscular use. Contains no preservative.
For use under Emergency Use Authorization.
After dilution store at 2 to 25°C (35 to 77°F) and
discard after 6 hours.
Dilution date and time:

NDC 59267-0078-1

FPO GS1 Data Bar Limited (RSS) - 7 mil
(01)10359267007817

Discard any unused vaccine **12 hours**
after dilution rather than **6 hours**.

06/20/2022 CS0210254H

1

Pfizer-BioNTech COVID-19 Vaccine Products At-A-Glance

Maroon cap: 6 Months through 4 Years of Age
Orange cap: 5 through 11 years of age
Gray or Purple cap: 12 years of age and older

The tables below summarize basic storage, preparation, scheduling, administration, and dosage for Pfizer-BioNTech COVID-19 Vaccine. Use this table in conjunction with materials below:

EUA Fact Sheet
www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/similarity-and-pfizer-biontech-covid-19-vaccine

CDC Interim Clinical Considerations
www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

CDC Clinical Materials
www.cdc.gov/vaccines/covid-19/info-by-product/pfizer

Interim COVID-19 Vaccination Schedule
<https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf>

Storage and Handling Basics

NOTE: Find additional guidance on storing the vaccine properly at:

- CDC's COVID-19 Clinical materials for Pfizer COVID-19 Vaccine: www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/storage.html
- CDC's Storage and Handling Toolkit: www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html

Vial cap color	Maroon Cap	Orange Cap	Gray Cap	Purple Cap
Ages	6 months through 4 years	5 through 11 years	12 years and older	
Supplied in multidose vial	10 doses per vial Requires diluent	10 doses per vial Requires diluent	6 doses per vial ! No diluent	6 doses per vial Requires diluent
Storage Temperature: Before Puncture	Between: -90°C and -60°C (-130°F and -76°F) until the expiration date ¹ 2°C and 8°C (36°F and 46°F) for up to 10 weeks ! Do NOT store vaccine in a standard freezer.			Between: -90°C and -60°C (-130°F and -76°F) until the expiration date ¹ -25°C to -15°C (-13°F to 5°F) for up to 2 weeks 2°C and 8°C (36°F and 46°F) for up to 1 month
Thawing Frozen Vaccine ! Do NOT refreeze thawed vaccine.	Between: 2°C and 8°C (36°F and 46°F). Amount of time needed varies based on temperature and number of vials. OR Up to 25°C (77°F) for 30 minutes			
Storage Temperature: After Puncture	Between: 2°C and 25°C (36°F and 77°F) for up to 12 hours. Discard vial and any unused vaccine after 12 hours.			Between: 2°C and 25°C (36°F and 77°F) for up to 6 hours. Discard vial and any unused vaccine after 6 hours.

¹ Vaccine expires 12 months after the manufacture date on the vial.

² Purple cap vaccine should not be used past the 12-month expiration. For vials with expiration dates of October 2021 through March 2022, the printed date on the label/carton reflects 6-month expiry. For vials with expiration dates of June 2022 through December 2022, the printed date on the label/carton reflects 9-month expiration date. The vaccine should not be used past the 12-month expiration date as noted in the HCP Fact Sheet.


06/24/2022 CS0310754H

1






Moderna & Pfizer Age Transition Job Aids



Moderna COVID-19 Vaccine


for Children who Transition from a Younger to Older Age Group




CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage **based on their age on the day of vaccination**.


- If a person moves from a younger age group to an older age group during the primary series, they should receive the vaccine product and dosage for the older age group for all subsequent doses.
- FDA emergency use authorization (EUA) allows for different dosing for certain age transitions, which are not considered vaccine administration errors and do not need to be reported to the Vaccine Adverse Event Reporting System (VAERS).

Children who turn from age 5 to age 6 years


 **Recommended:** Children who started a primary series and turned from age 5 to age 6 years before completion of the series should receive:


Dose 1 (Age 5):
0.25 mL (25 mcg) of the product authorized for children ages 6 months–5 years (dark blue cap/magenta label border)




4–8 weeks

Child turns 6

Dose 2 (Age 6):
0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/purple label border)




 **Acceptable:** If the following dosing occurs, it is NOT considered an error and the primary series is considered complete. Either dose may be:


- 0.25 mL (25 mcg) of the product authorized for children ages 6 months–5 years (dark blue cap/magenta label border), or
- 0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/purple label border)

Dose 1: Age 5



OR




4–8 weeks



OR




06/23/2022 CS3215714 1 2



Pfizer-BioNTech COVID-19 Vaccine


for Children who Transition from a Younger to Older Age Group




CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage **based on their age on the day of vaccination**.


- If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine product and dosage for the older age group for all subsequent doses.
- FDA emergency use authorization (EUA) allows for different dosing for certain age transitions, which are not considered vaccine administration errors and do not need to be reported to the Vaccine Adverse Event Reporting System (VAERS).

Children who turn from age 4 to age 5 years


 **Recommended:** Children who started a primary series and turned from age 4 to age 5 years between dose 1 and dose 2 in the primary series should receive:

Dose 1 (Age 4):
0.20 mL (3 mcg) of the product authorized for children ages 6 months–4 years (maroon cap and label border)




3–8 weeks

Child turns 5


Dose 2 (Age 5):
0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border)




8 weeks

Dose 3 (Age 5):
0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border)




 **Recommended:** Children who started a primary series and turned from age 4 to age 5 years between dose 2 and dose 3 in the primary series should receive:


Dose 1 (Age 4):
0.20 mL (3 mcg) of the product authorized for children ages 6 months–4 years (maroon cap and label border)




3–8 weeks


Dose 2 (Age 4):
0.20 mL (3 mcg) of the product authorized for children ages 6 months–4 years (maroon cap and label border)




8 weeks

Child turns 5

Dose 3 (Age 5):
0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border)




 **Acceptable:** If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.

- A 2-dose primary series using the Pfizer-BioNTech COVID-19 Vaccine product authorized for children ages 5–11 years (orange cap and label border)

Dose 1: Age 4 or 5


3–8 weeks

Dose 2: Age 4 or 5


06/23/2022 CS3215714 1 2


HHS*: COVID-19 Public Education Toolkit

Toolkit includes:

- Informational Content
- Posters & Flyers
- Social Media
- AAP** Videos
- And more...

[HHS Pediatricians and Family Physicians Toolkit: English](#)

[HHS Pediatricians and Family Physicians Toolkit: Spanish](#)



The screenshot shows the 'COVID-19 Public Education Campaign' website. The header includes the 'WE CAN DO THIS' logo and navigation links: 'Shareable Resources', 'Outreach Tools', 'About the Campaign', and 'Get Involved'. The main content area is titled 'Pediatricians and Family Physicians Toolkit'. It features a language selection dropdown menu with options for 'English' and 'Spanish'. Below the menu, there is a paragraph describing the toolkit's purpose: 'This toolkit has resources for pediatricians and family physicians who want to help increase confidence in and uptake of COVID-19 vaccines among their patients and in the communities they serve. Developed in partnership with the American Academy of Pediatrics, it includes information from CDC and new, culturally tailored materials from the HHS COVID-19 Public Education Campaign and its team of multicultural experts.' The bottom of the page displays a collage of six images showing healthcare professionals interacting with patients, all wearing face masks.

VA58 Trust & Safety Team Updates

The VA58 Trust & Safety Team reports on trending narratives about COVID-19, delivers biweekly briefings, and develops comprehensive resources to increase awareness around mis-, dis-, and mal-information, as well as the State's capacity to counter it.

BIWEEKLY BRIEFINGS

Biweekly briefings provide partners with the top COVID-19 vaccine mis/dis topics and trends, and invitees receive a copy of the report post-briefing.

To be added to the invite, email
rumors@cdph.ca.gov.


RUMORS INBOX

The Rumors Inbox serves as a tip line for our partners to submit the COVID-19 rumors they're hearing online and within their communities to our team. We incorporate the submissions into our team's reporting.



Report COVID-19 Vaccine Rumors to:

rumors@cdph.ca.gov



RECENT TOPICS & RESOURCES

Mis/Dis/Mal-information: CDC's under-5 vaccine approval disregards myocarditis and other risks

Trusted Resources: [Myocarditis and Pericarditis After mRNA COVID-19 Vaccination | CDC \(Spanish\)](#), [CDC Recommends COVID-19 Vaccines for Young Children | CDC Online Newsroom | CDC](#), [What should parents know about the COVID vaccine for kids under 5? - HealthyChildren.org](#), [COVID-19 Community Health & Workplace Outreach Projects | California COVID-19 Community Health & Workplace Outreach Projects Official Brand Assets | Brandfolder](#)

Mis/Dis/Mal-information: Vaccine dosage is too potent for infants and small children


Trusted Resources: [COVID Vaccines for Kids 6 Months & Older: FAQs for Families - HealthyChildren.org](#), [COVID-19 Vaccine: Frequently Asked Questions \(aap.org\)](#), [COVID-19 Vaccination for Children | CDC](#)

Stay informed!

Provider Resources on eziz.org/covid

Frequent Content Updates:

- Alerts
- Program Enrollment
- My Turn Onboarding
- Reporting Requirements
- Patient Resources
- Archived Communications
- Education & Support Materials
- More to explore!

**Vaccinate
ALL 58**

California COVID-19 Vaccination Program

ENHANCED BY Google

Program Updates

Program Enrollment

My Turn Onboarding

Vaccine Management

Vaccine Administration

Reporting Requirements

Archived Communications

Patient Resources

Provider Support

COVID Call Center

Email: [Program Info](#)

Phone: (833) 502-1245

Hours: Mon-Fri, 8AM-6PM

Contact us for questions about the program or help with accessing documents.

myCAvax and My Turn

Email: [myCAvax Technical Support](#)
[MyTurn Onboarding](#),
[MyTurn Technical Support](#)

Phone: (833) 502-1245

Mon-Fri, 7AM-7PM

Sat-Sun, 8AM-1PM

My Turn Clinic Translation Line:
(833) 980-3933


Mon-Fri: 8AM-8PM


Sun-Sat: 8AM-5PM


Vaccines


[Manufacturer Contacts](#)

Updates for Providers

FAQs

Provider Office Hours

myCAvax Training

Training Calendar

Alerts:

Updated Infant/Toddler Recommendations and Products

- Routine and Small Orders are now open for the Infant/Toddler products. Expect delivery to begin after the wave 2 pre-order delivery window is complete after Wednesday, June 29. [View Pre-Ordering/Delivery Schedule](#)
- [Interim Clinical Considerations for Use of COVID-19 Vaccines \(CDC\)](#)
- [Summary of Pfizer 6 months-4 years and Moderna 6 months-5 years Vaccines \(CDPH\)](#)
- [COVID-19 Vaccination Schedule \(Timing Guide\)](#)-CDPH version back by popular demand!
- [Guide of COVID-19 Vaccine Products](#)

Planning Resources

- [Preparing for Infant/Toddler Vaccinations Job Aid](#)
- [Planning for Under 5 Vaccinations Webinar Recording and Slides](#)
- [Recommending COVID-19 Vaccination: Clinical Talking Points 6/17/22](#)
- [Requesting COVID-19 Vaccination Staff](#)
- [Expanding Vaccination Capacity](#)

Now Enrolling Providers of Pediatric Services

- [Find Information on How to Enroll](#)
- [Dispelling Provider Myths About Joining the California COVID-19 Vaccination Program](#)
- [Welcome VFC Providers | Flyer | VFC vs. COVID Programs](#)

Featured Resources

Tools to Avoid Vaccine Mix-Ups:

- [Vaccine Administration Checklist 6/21/22](#)
- [Preventing Administration Errors 6/21/22](#)
- [Coadministration of COVID-19 Vaccine with Other Vaccines | Tips | Preteens](#)
- [Tips to Ease Anxiety During Vaccination](#)

COVID-19 Vaccine Provider FAQs

- Answers to provider questions
- Updated weekly: last updated 06/30/2022
- Currently in its 78th iteration!



Q: If a child moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), which dosage should they receive?

A: Children should receive the age-appropriate formulation and follow the [vaccine eligibility schedule](#) based on their age on the day of vaccination, regardless of their size or weight. If a child moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine dosage for the older age group for all subsequent doses. For further information, please see [Moderna Age Transition Job Aid](#), [Pfizer Age Transition Job Aid](#), and [CDC Interim Clinical Considerations: Appendix C](#).



Q: Now that COVID-19 vaccine eligibility has expanded, have minor consent requirements changed?

A: No, minor consent requirements have not changed. Minors still need the consent of the parent or legal guardian to receive the COVID-19 vaccine. An emancipated minor (a minor with legal independence from their parents or guardians) may consent for their self. Minor consent can be given through My Turn or through the [COVID-19 Vaccine Minor Consent Form in English](#) and [in Spanish](#).

California COVID-19 Vaccination Program Provider FAQs

For Prospective, Newly Enrolled, and Current California COVID-19 Vaccine Providers. Providers may also visit [California COVID-19 Vaccination Program](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

Contents

New and Updated FAQs.....	2
Pediatric Providers	5
Vaccine Program Management.....	5
Provider Enrollment	6
Ordering.....	6
Distribution/Redistribution.....	7
Vaccine Administration.....	7
Additional/Booster Doses.....	9
Vaccine Storage & Handling.....	10
Inventory.....	10
Reporting	10
Billing & Reimbursement.....	11
Communication Resources	12

[Provider FAQs on EZIZ, Updated Weekly](#)



COVID-19 Vaccination Program Webinars and Training for Providers

Week of July 4, 2022

Note: Calendar subject to change

	Monday 7/4	Tuesday 7/5	Wednesday 7/6	Thursday 7/7	Friday 7/8
myCAvax, My Turn, and Combined Office Hours and Events	Holiday	Pfizer BioNTech COVID-19 Vaccine Training & Education* 12:00 pm – 1:00 pm PW: GBg5xe59Tjp	Pfizer BioNTech COVID-19 Vaccine Training & Education* 9:00 am – 10:00 am PW:hJ7MC4Fdfh2	Pfizer BioNTech COVID-19 Vaccine Training & Education* 9:00 am – 10:00 am PW: wuRUgnz9P24	Provider Office Hours 9:00 am – 10:00 am Pfizer BioNTech COVID-19 Vaccine Training & Education* 12:00 pm – 1:00 pm PW:yvHkBM8Dm33

* Pfizer topics vary by day and include the latest information about use of each vaccine presentation, including storage, handling, preparation, and administration; recent medical updates and FDA authorizations, healthcare provider resources, and a Q&A session.

View On Demand	<ul style="list-style-type: none">Intro to My Turn Onboarding (v. 1/4/22)Latest Features in My Turn (*Requires My Turn Login)	<ul style="list-style-type: none">Latest Features in myCAvax for Providers (*Requires myCAvax Login)myCAvax Release Notes for LHJs and CDPH Users (*Requires myCAvax Login)COVID-19 Crucial Conversations Archived Webinars and Slides	<ul style="list-style-type: none">Provider 101 Account Enrollment: Section A: Organization Application (v. 10/21/21)Provider 101 Account Enrollment: Section B: Location Application (v. 10/21/21)Provider Office Hours and MCE Office Hours Archived Sessions
----------------	--	--	--

Help

Website: www.eziz.org/covid, [FAQs](#)
General email: covidcallcenter@cdph.ca.gov
CDPH Provider Call Center: 1-833-502-1245, 8am-6pm

My Turn email: myturnonboarding@cdph.ca.gov
myCAvax Help Desk Email: myCAvax.HD@accenture.com
Phone: (833) 502-1245



Update: Delayed Medi-Cal Claims Submissions: Pfizer Infant Toddler (6mos-4yrs) & Moderna (6mos-17yrs)

- Department of Health Care Services (DHCS) is aggressively pursuing the necessary system and operational changes required to enable successful claims adjudication for administration of the Pfizer-BioNTech and Moderna COVID-19 vaccines for this age range.
- Medi-Cal will announce when the claims adjudication system is prepared to appropriately adjudicate submitted claims, as well as any additional instruction providers should utilize when billing.
- Until then, providers are advised to administer the primary vaccination series to eligible children, based on recommendations from the FDA and Centers for Disease Control and Prevention (CDC), and hold the claim submission until further notice.

KidsVaxGrant

Thomas Villagomez, CDPH

KidsVaxGrant 2.0 – Coming July 2022!

- The California Department of Public Health has appropriated approximately \$10 million to support KidsVaxGrant 2.0.
- Up to \$25,000 to support eligible providers of pediatric services administering the COVID-19 vaccine.

More details coming soon!

Bookmark KidsVaxGrant.org to stay up to date or email us at Kidsvaxgrant@phcdocs.org to be added to our email list




Vaccine Administration Data

Elizabeth Reosti, CDPH

Vaccine Administration Summary

as of June 27, 2022

Primary Series Completion (Total CA Population)
Primary Series Completion (Ages 5-11)
Primary Series Completion (Ages 18+)
Booster Eligible Completion



77,359,712

Total Doses Administered:

Select Status Category

Total Eligible Population ▼

Received Booster

Booster eligible but not received


Primary series complete, Booster ineligible

Primary series incomplete

Not yet vaccinated

Statewide comparison, selected metric

Statewide overall




**Booster/Additional
Dose Recipients:
16,045,706**


Trends in Vaccine Administration

as of June 27, 2022

Daily Doses Administered: **Statewide**



Weekly Doses Administered: **Statewide** (thousands)



Trends in Vaccine Administration

as of June 27, 2022


New Booster Eligibility Driving Demand

- Second boosters among 50+ year-olds
- First boosters among 5-to-11-year-olds

FDA NEWS RELEASE

Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Vaccine Booster Dose to Children 5 through 11 Years

For Immediate Release: May 17, 2022




5-to-11-Year-Old Vaccination Trends

as of June 27, 2022

Weekly New 5-11 year-old Partially Vaccinated Recipients by VEM: **Statewide**

Recent decrease in first doses among 5-to-11- year-olds



1st Booster Vaccination Rates

as of June 27, 2022

CDC Strengthens Recommendations and Expands Eligibility for COVID-19 Booster Shots

Media Statement

For Immediate Release: Thursday, May 19, 2022


Contact: [Media Relations](#)

(404) 639-3286

Following today's meeting of the Advisory Committee on Immunization Practices' (ACIP), CDC is expanding eligibility of COVID-19 vaccine booster doses to everyone 5 years of age and older. CDC now recommends that children ages 5 through 11 years should receive a booster shot 5 months after their initial Pfizer-BioNTech vaccination series. Since the pandemic began, more than 4.8 million children ages 5 through 11 have been diagnosed with COVID-19, 15,000 have been hospitalized and, tragically, over 180 have died. As cases increase across the country, a booster dose will safely help restore and enhance protection against severe disease.

In addition, today CDC is strengthening its recommendation that those 12 and older who are immunocompromised and those 50 and older should receive a second booster dose at least 4 months after their first. Over the past month we have seen steady increases in cases, with a steep and substantial increase in hospitalizations for older Americans. While older Americans have the highest coverage of any age group of first booster doses, most older Americans received their last dose (either their primary series or their first booster dose) many months ago, leaving many who are vulnerable without the protection they may need to prevent severe disease, hospitalization, and death.

Received Booster 50+ (among booster-eligible population)



American Indian/Alaska Native 61%; Multiracial 84%; Native Hawaiian and Pacific Islander 68%; Other Race 53%.

Booster rate estimates for some groups, such as Native Hawaiian and other Pacific Islander and multi-race populations, may be unreliable. This is because of differences between how demographic data is collected through Census estimates and how information is collected at the time of vaccination.

Data Summary

as of June 27, 2022

Latest Metrics

77.4 Million doses administered

228K doses administered in previous week (-10% pt. change)

5,243 new 5-to-11-year-old recipients (-3% pt. change)

System Updates

- 4th doses are included in the overall dose admin count, but not currently displayed in immunization status.
- Vaccines approved for children 6 months and older (Pfizer and Moderna).

Clinical Update

Floria Chi, M.D., CDPH

Moderna 6 Years -17 Years COVID-19 Vaccines Authorized Under Emergency Use and Recommended by CDC/ACIP

- The Food and Drug Administration's (FDA) Vaccine Related Biologic Products Advisory Committee (VRBPAC) voted to support and the FDA authorized emergency use authorization (EUA) of:
 - Moderna vaccine for 6 through 17 years
 - Moderna vaccine for 6 months through 5 years
 - Pfizer vaccine for 6 months through 4 years
- The CDC's Advisory Committee on Immunization Practices (ACIP) and Western States Scientific Safety Review Workgroup (WSSSRW) recommend:

June 18, 2022


- Moderna vaccine for 6 months through 5 years
- Pfizer vaccine for 6 months through 4 years

June 23, 2022

- Moderna vaccine for 6 Years through 17 years.

Rates of COVID-19 cases by vaccination status and age group


April 04, 2021 – April 23, 2022 (31 U.S. Jurisdictions)



CDC COVID Data Tracker. <https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status> Accessed May 20, 2022


Rates of monthly COVID-19-associated hospitalizations by vaccination status among children and adolescents 5–17 years, COVID-NET

June 2021 – April 2022



Source: CDC COVID Data Tracker: COVID-NET Hospitalizations by Vaccination Status. Accessed June 20, 2022.

Timeframe of Randomized Controlled Trials



Source: COVID Data Tracker, https://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases. Accessed 6/16/2022

Summary of GRADE Children Ages 6–11 Years

Outcome	Importance	Design (# of studies)	Findings	Evidence type
Benefits				
1a. Symptomatic lab-confirmed COVID-19 (efficacy)	Critical	RCT (1)	Moderna COVID-19 vaccine is effective in preventing symptomatic COVID-19	2
1b. Symptomatic lab-confirmed COVID-19 (immunobridging)	Critical	RCT (1)	Moderna COVID-19 vaccine is effective in preventing symptomatic COVID-19	2
2. Hospitalization due to COVID-19	Important	No studies	Data not available from any studies	ND
3. Multisystem inflammatory syndrome in children (MIS-C)	Important	No studies	Data not available from any studies	ND
4. Asymptomatic SARS-CoV-2 infection	Important	RCT (1)	The vaccine may prevent asymptomatic SARS-CoV-2 infection, however certainty in the estimate was low	3
Harms				
5. Serious adverse events	Critical	RCT (1)	6 participants with SAEs among vaccinated and 2 among unvaccinated; certainty in the estimate was very low. No SAEs were judged to be related to vaccination.	4
6. Reactogenicity	Important	RCT (1)	Severe reactions were more common in vaccinated; any grade ≥ 3 reaction was reported by 17.0% of vaccinated vs. 3.3% of placebo group	1

Evidence type: 1=high; 2=moderate; 3=low; 4=very low; ND, no data

Summary of GRADE


Adolescents ages 12–17 years

Outcome	Importance	Design (# of studies)	Findings	Evidence type
Benefits				
1a. Symptomatic lab-confirmed COVID-19	Critical	RCT (1)	Moderna COVID-19 vaccine is effective in preventing symptomatic COVID-19	2
1b. Symptomatic lab-confirmed COVID-19	Critical	RCT (1)	Moderna COVID-19 vaccine is effective in preventing symptomatic COVID-19	2
2. Hospitalization due to COVID-19	Important	No studies	Data not available from any studies	ND
3. Multisystem inflammatory syndrome in children (MIS-C)	Important	No studies	Data not available from any studies	ND
5. Asymptomatic SARS-CoV-2 infection	Important	RCT (1)	The vaccine did not demonstrate efficacy in prevention of asymptomatic SARS-CoV-2 infection	3
Harms				
6. Serious adverse events	Critical	RCT (1)	6 participants with SAEs among vaccinated and 2 among unvaccinated; certainty in the estimate was very low. No SAEs were judged to be related to vaccination.	4
7. Reactogenicity	Important	RCT (1)	Severe reactions were more common in vaccinated; any grade ≥ 3 reaction was reported by 25.3% of vaccinated vs. 4.8% of placebo group	1


Evidence type: 1=high; 2=moderate; 3=low; 4=very low; ND, no data

Pediatric Schedule: People Who Are NOT Moderately or Severely Immunocompromised


Moderna
(6 months–
17 years)



Pfizer-BioNTech
(6 months–
4 years)



Pfizer-BioNTech
(5 years–
17 years)



AT-A-GLANCE

COVID-19 Vaccination Schedules

Use the schedules below to determine how many total COVID-19 vaccine doses are recommended based on primary series product, age, and immune status. This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

COVID-19 Vaccination Schedule for Most People

Considerations for Extended Interval Between Dose 1 & 2

- Immunocompromised
- High risk for severe disease
- Household member with high risk for severe disease
- High COVID-19 community levels



- Reduced myocarditis risk
- Adolescent and young adult males
- Optimize vaccine effectiveness

Pediatric Schedule: People Who ARE Moderately or Severely Immunocompromised


Moderna
(6 months–
17 years)



Pfizer-BioNTech
(6 months–
4 years)



Pfizer-BioNTech
(5 years–
11 years)



Pfizer-BioNTech
(12 years–
17 years)




Moderna COVID-19 Vaccine Products

Authorized Age group	 6 months–5 years (primary series)	 <ul style="list-style-type: none"> • 6–11 years (primary series) • 18 years and older (booster doses) 	 <ul style="list-style-type: none"> • 12 years and older (primary series) • 18 years and older (booster doses)
Vial cap color	Dark blue	Dark blue	Red
Label border color	Magenta	Purple	Light blue
Dose (mRNA concentration)	25 mcg	50 mcg	100 mcg
Injection volume	0.25 mL	0.5 mL	0.5 mL (primary, age 12+); 0.25 mL (booster, age 18+)
Dilution required	No	No	No
Doses per vial	10	5	Maximum of 11


Children who Turn from Age 5 to 6 Years Between Any Dose in the Primary Series May Receive...

...for either dose: 1) The Moderna product authorized for children ages 6 months–5 years or 2) the Moderna product authorized for children ages 6–11 years.




Children who Turn from Age 11 to 12 Years Between Any Dose in the Primary Series May Receive...

...for either dose: 1) the Moderna product authorized for children ages 6–11 years, 2) The Moderna product authorized for children ages 12–17 years.



CDC Guidance for Age Transition Job Aids & Pediatric Mixed Series



Appendix C: Table C. Interim recommendations for COVID-19 vaccine administration errors and deviations

Type	Administration error/deviation	Interim recommendation
Mixed series	<ul style="list-style-type: none">Incorrect mRNA COVID-19 vaccine product inadvertently administered as part of a 2- or 3-dose primary series	<ul style="list-style-type: none">Do not repeat dose.Children ages 6 months–4 years who receive different mRNA products for the first 2 doses of an mRNA COVID-19 vaccine series should follow a 3-dose schedule. A third dose of either mRNA vaccine should be administered 8 weeks after the second dose to complete the 3-dose primary series.Children ages 5–17 years who receive a mixed mRNA COVID-19 vaccine primary series can follow the Pfizer-BioNTech COVID-19 Vaccine schedule and receive a booster dose.

Resources: Preventing Vaccine Administration Errors

- Web-on-demand “mini” webinar:

Web-on-Demand "Mini" Webinar

- Vaccine Administration: Preventing Vaccine Administration Errors

Preventing Vaccine Administration Errors

- Vaccine storage, handling, preparation, and administration materials:

Vaccine S&H, Preparation, and Administration Materials

YOU CALL THE SHOTS Vaccine Administration: Preventing Vaccine Administration Errors

A vaccine administration error is any preventable event that may cause or lead to inappropriate medication use or patient harm.¹ Vaccine administration errors can have many consequences, including inadequate immunological protection, possible injury to the patient, cost, inconvenience, and reduced confidence in the health care delivery system. Take preventive actions to avoid vaccine administration errors and establish an environment that values reporting and investigating errors as part of risk management and quality improvement.

Vaccine administration errors may be due to causes such as:

- Insufficient staff training
- Distraction
- Changes in recommendations
- Lack of standardized protocols
- Patient misidentification
- Using nonstandard or error-prone abbreviations
- Easily misidentified products (e.g., DTaP, DT, Tdap, Td)

If an error occurs, determine how it occurred and take the appropriate actions to put strategies in place to prevent it from happening in the future. The following table outlines common vaccine administration errors and possible preventive actions you can take to avoid errors.

Error(s)	Possible Preventive Actions
Wrong vaccine, route, site, or dosage (amount) or improperly prepared.	<ul style="list-style-type: none">Circle important information on the packaging to emphasize the difference between the vaccines.Include the brand name with the vaccine abbreviation whenever possible (e.g., PCV13 [Pneumovax13] in orders, medical screens, etc.).Separate vaccines into bins or other containers according to type and formulation. Use color-coded identification labels on vaccine storage containers.Store look-alike vaccines in different areas of the storage unit (e.g., pediatric and adult formulations of the same vaccine on different shelves in the unit).Do not list vaccines with look-alike names sequentially on computer screens, order forms, or medical records, if possible.Consider using "name alert" or "look-alike" stickers on packaging and areas where these vaccines are stored.Consider purchasing products with look-alike packaging from different manufacturers, if possible.Establish "Do NOT Disturb" or no-interruption areas or times when vaccines are being prepared or administered.Prepare vaccine for one patient at a time. Once prepared, label the syringe with vaccine name.Do not administer vaccines prepared by someone else.Triple-check work before administering a vaccine and ask another staff member to check.Keep reference materials on recommended sites, routes, and needle lengths for each vaccine used in your facility in the medication preparation area.Clearly identify diluents if the manufacturer's label could mislead staff into believing the diluent is the vaccine itself.Integrate vaccine administration training into orientation and other appropriate education requirements.Provide education when new products are added to inventory or recommendations are updated.Use standing orders, if appropriate.

Preventive Actions

- Identify before administering vaccines.
- The importance of avoiding unnecessary distractions or interruptions when staff is vaccine.
- Administer vaccines to one patient at a time. If more than one patient needs vaccines (clinical encounter (e.g., parent with two children), assign different providers to each. Alternatively, bring only one patient's vaccines into the treatment area at a time, one and patient name.
- Prepare abbreviations to document vaccine administration (e.g., use intramuscular route on the intramuscular route – not IM, which is easily confused with IM).
- Abbreviations.
- Avoidance of look-alike names or generic abbreviations on computer screens, if possible.
- Storage and handling training based on manufacturer guidance and/or:
- To those with the earliest expiration dates are in the front of the storage unit. Use
- Vaccines/bloods from storage units and areas where stable vaccines are stored.
- Exposure to improper temperatures and contact the state or local immunization
- The vaccine manufacturer.
- Yes, if appropriate.
- In to obtain a complete vaccination history using the immunization information
- Your medical records, and personal vaccination records.
- Administration training, including timing and spacing of vaccines, into orientation
- Update education requirements.
- Initially infers, schedule immunization visits after the birthday.
- Vaccination schedules for children and adults that staff can quickly reference in clinical
- Settings may be prescribed and administered.
- Alerts for timing and spacing in your medication preparation area. CDC has vaccine
- For DTaP, Tdap, Hib, PCV13, and polio vaccines to assist health care personnel in
- Catch-up schedule for children.
- And patients on how important it is for them to maintain immunization records.
- To report vaccine administration errors to
- ADR.
- To file an electronic report, please see the

1. National Coordinating Council for Medication Error Reporting and Prevention. <http://www.nccmerpen.org/medication-errors>

© 2015 CDC. 11-00004

Vaccine Administration: Preventing Vaccine Administration Errors

* At this time, COVID-19 vaccination has additional VAERS reporting requirements, including required reporting of vaccine administration errors. Please see <https://www.cdc.gov/vaccine/errors> for more information.

© 2020 CDC. 11-00004

U.S. Department of Health and Human Services

CDC



COVID-19 Vaccine Timing by Age

Job Aid Includes:


- Pediatric Routine
- Pediatric Immunocompromised
- Adolescent & Adult Routine
- Adolescent & Adult Immunocompromised

CDC Interim Clinical Considerations


COVID-19 Vaccine Timing–Pediatric					
Routine Schedule					
Age	Vaccine	Primary Doses			Booster Dose
6 months–4 years	Pfizer–Infant/Toddler	1st Dose	3–8 weeks*	2nd Dose	≥8 weeks → 3rd Dose
6 months–5 years	Moderna–Infant/Toddler	1st Dose	4–8 weeks*	2nd Dose	
5–11 years	Pfizer–Pediatric	1st Dose	3–8 weeks*	2nd Dose	≥5 months → Booster
6–11 years	Moderna–Pediatric	1st Dose	4–8 weeks*	2nd Dose	
Schedule if Moderately or Severely Immunocompromised					
Age	Vaccine	Primary Doses			Booster Dose
6 months–4 years	Pfizer–Infant/Toddler	1st Dose	3 weeks	2nd Dose	≥8 weeks → 3rd Dose
6 months–5 years	Moderna–Infant/Toddler	1st Dose	4 weeks	2nd Dose	≥4 weeks → 3rd Dose
5–11 years	Pfizer–Pediatric	1st Dose	3 weeks	2nd Dose	≥4 weeks → 3rd Dose → ≥3 months → Booster
6–11 years	Moderna–Pediatric	1st Dose	4 weeks	2nd Dose	≥4 weeks → 3rd Dose
<small>^ An 8-week interval may be preferable for some people, especially for males 12–39 years.</small>					
<small>* Although use of mRNA COVID-19 vaccines is preferred, the Janssen vaccine may be offered in some situations.</small>					
<small>View Interim Clinical Considerations for Use of COVID-19 Vaccines for details. Schedule is subject to change.</small>					
California COVID-19 Vaccination Program					IMM-1396 (6/28/22) Page 1 of 3

COVID-19 Vaccine Timing by Age (continued)

Routine Schedule



Moderately or Severely Immunocompromised



Management of Anaphylaxis at COVID-19 Vaccination Sites: Pediatric Epinephrine Dosing

- In children, administer 0.01mg/kg intramuscular dose (which may only be possible in certain clinics or medical offices), or administer a standard dosage using the epinephrine autoinjector.
 - For children 15 kg (33 lbs.) to <30 kg (66 lbs.), administer the 0.15 mg epinephrine autoinjector ([FDA product insert](#)). The 0.15mg epinephrine autoinjector can also be used for children 7.5 kg (16.5 lbs.) to <15 kg (33 lbs.) when other alternatives are not available ([American Academy of Pediatrics](#)).
 - For children ≥30 kg (66 lbs.), administer the 0.30 mg epinephrine autoinjector ([FDA product insert](#)).
- COVID-19 vaccination locations should have **at least 3 doses** of age-appropriate epinephrine available at all times.

Epinephrine

First-Line Treatment: Epinephrine

Recommended dose is 0.01 mg/kg body weight up to 0.5 mg maximum dose. May be repeated every 5–15 minutes (or sooner) up to 3 times while waiting for EMS to arrive.

First-Line Treatment: Epinephrine				Epinephrine Dose	
	Age group	Range of weight (lb)	Range of weight (kg)*	1.0 mg/mL aqueous solution (1:1000 dilution); intramuscular. Minimum dose: 0.05 mL	Epinephrine autoinjector or prefilled syringe (0.1 mg, 0.15 mg, 0.3 mg)
Infants and children	1–6 months	9–19 lb	4–8.5 kg	0.05 mL (or mg)	off label
	7–36 months	20–32 lb†	9–14.5 kg†	0.1 mL (or mg)	0.1 mg†
	37–59 months	33–39 lb	15–17.5 kg	0.15 mL (or mg)	0.15 mg/dose
	5–7 years	40–56 lb	18–25.5 kg	0.2–0.25 mL (or mg)	0.15 mg/dose
	8–10 years	57–76 lb	26–34.5 kg	0.25–0.3 mL (or mg)	0.15 mg or 0.3 mg/dose
Teens	11–12 years	77–99 lb	35–45 kg	0.35–0.4 mL (or mg)	0.3 mg/dose
	13 years & older	100+ lb	46+ kg	0.5 mL (or mg) – max. dose	0.3 mg/dose

NOTE: If body weight is known, then dosing by weight is preferred. If weight is not known or not readily available, dosing by age is appropriate.

* Rounded weight at the 50th percentile for each age range

† 0.1 mg autoinjector is licensed for use in 7.5 to 14 kg infants and children


**175th Vaccines and Related Biological Products Advisory Committee
(VRBPAC) Meeting June 28, 2022**

VOTING QUESTION

Does the committee recommend inclusion of a SARS-CoV-2 Omicron component for COVID-19 booster vaccines in the United States?

Provider Office Hours Q&A

During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.



Storage & Handling

Kate McHugh, CDPH

COVID-19 Vaccine Product Guide

COVID-19 Vaccine Product Guide



Check vaccine labels and [EUA fact sheets](#) before use to avoid mix-ups. [EUA fact sheets](#) supersede info on vials and carton. Refer to [CDC Product Guide](#) for more information.

	Pfizer			Moderna			Janssen (J&J)
	Infant/Toddler 6 months–4 years*	Pediatric 5–11 years	Adol/Adult 12+ years	Infant/Toddler 6 months–5 years	6–11 years: primary* 18+ years: booster	12+ years: primary 18+ years: booster	Adult 18+ years
Packaging	Maroon Cap	Orange Cap	Gray Cap	Dark Blue Cap	Dark Blue Cap	Red Cap	Blue Cap
Doses Per Vial	10 doses	10 doses	6 doses	10 doses	5 doses	10–11 doses	5 doses
Carton Size	100 doses	100 doses	60 doses	100 doses	50 doses	100 doses	50 doses
Min. Standard Order	100 doses	100 doses	300 doses	100 doses	100 doses	100 doses	100 doses
NDC-Unit of Use (vial)	59267-0078-01	59267-1055-01	59267-1025-01	80777-0279-05	80777-0275-05	80777-0273-10	59676-0580-05
CVX Code	219	218	217	228	221	207	212
Storage Limits Before Puncture: Label vaccine with expiration and use-by dates. Strictly comply with manufacturer guidance.							
ULT (-90°C to -60°C)	Until expiration	Until expiration	Until expiration				
Thermal Shipper							
Freezer				Until expiration (-50°C to -15°C)	Until expiration (-50°C to -15°C)	Until expiration (-50°C to -15°C)	
Refrigerator (2–8°C)	Up to 10 weeks	Up to 10 weeks	Up to 10 weeks	Up to 30 days	Up to 30 days	Up to 30 days	Until expiration
Checking Expiration Dates [†]	12 months from manufacture date. Check FDA fact sheet.	12 months from manufacture date. Check FDA fact sheet.	12 months from manufacture date. Check FDA fact sheet.	Check product website or QR code	Check product website or QR code	Check product website or QR code	Check product website , QR code, or call 800-565-4008

* Labels for Pfizer Maroon Cap and Moderna Booster products may not reflect expanded age ranges.

† Do not dispose of expired vaccine until checking with manufacturers for extended expiration dates.

California COVID-19 Vaccination Program

IMM-1399 (6/29/22)

COVID-19 Vaccine Product Guide



Moderna

6–11 years: primary
18+ years: booster

12+ years: primary*
18+ years: booster

Janssen (J&J)

Adult
18+ years

Do not dilute.

0.5 mL
(50 mcg dose)

0.5 mL
(only ages 18+)

2 hours
(Let vial stand at
room temp for
15 min before
administering.)

45 minutes at
15° to 25°C
(59° to 77°F)

Store up to 24
hours at 8°C to
25°C (46°F to 77°F)

Discard after
12 hours at 2°C to
25°C (36°F to 77°F)

Do not dilute

0.5 mL
(100 mcg dose)

0.25 mL*
(only ages 18+)

2.5 hours
(Let vial stand at
room temp for 15
minutes before
administering.)

1 hour at
15° to 25°C
(59° to 77°F)

Store up to 24
hours at 8°C to 25°C
(46°F to 77°F)

12 hours at 2°C to
25°C (36°F to 77°F)
Discard after 20
punctures.

Do not dilute

0.5 mL

0.5 mL

If needed immedi-
ately, thaw at room
temperature

Carton: up to 4 hrs
Vial: about 1 hour at
25°C (77°F) max

Store up to 12
hours at 9°C to 25°C
(47°F to 77°F)

6 hours at 2° to 8°C
(36°F to 46°F) or
2 hours at 25°C
(77°F) max

IMM-1399 (6/29/22)

Moderna Ages 6 Years -11 Years

- **Blue cap** and **purple border**
- Misabeled – says booster dose only but can be used for primary doses for ages 6-11
 - When ordering, providers should be ordering with the primary purpose to use in ages 6-11, but they can also be used for adult booster doses.
- 5 doses per vial
- 0.5mL injection volume
- Same storage conditions as the other Moderna products
 - -50C to –15C for long-term storage
 - 2C to 8C for up to 30 days in the fridge
- Letter explaining the mislabeling



Moderna Infant/Toddler Vaccine Video Trainings



Link to Video Resources



[How to Withdraw a 0.25mL dose: Infant/Toddler 6 months-5 years](#)



[How to Withdraw a 0.5mL Dose for Pediatrics 6 Years-11Years](#)

US-COV-2200159 06/2022

Pfizer COVID-19 Vaccine Updates & Trainings

Date & Time (linked)	Password
Friday, July 01 - 12PM	QMjNKiQX532
Tuesday, July 05 - 12PM	GBg5xe59Tjp
Wednesday, July 06 - 9AM	hJ7MC4Fdfh2
Thursday, July 07 - 9AM	wuRUgnz9P24
Friday, July 08 - 12PM	yvHkBM8Dm33
<p>More sessions listed!</p> <p>NOTE: All times listed here are PDT.</p>	

Audience:


Providers and immunization staff

Session Topics Include:

- Potential new vaccine presentation (**Maroon Cap**) for individuals 6 months through 4 years of age** (Starting June 7)
- FDA approvals, authorizations - including recent authorizations
- Extended expiry for **Purple**, **Orange**, and **Gray Cap**
- **Gray Cap**, Comirnaty®
- Use of each vaccine presentation, including storage, handling, preparation, and administration

Infant/Toddler COVID-19 Vaccine Preparation and Administration Summary

Vaccine
with an
n)
children
death
ements
use of an
A
s
ed to
accine
arer's
and
tors,
[radio-c](#)
nated,
after a
nssen)
cine
dren
mRNA
erations
United
[civ](#)
ions,
e, blood
ing, stridor),




Vaccine
 with an
 on)
 children
 death
 rements
 r use of an
 JA
 is
 ged to
 vaccine
 f
 urer's
 and
 rrors,
[product/](#)

aneous
 s with
 elicited the
 are,
 vaccine

lerations
 e United
[act/](#)

NEW

Infant/Toddler Vaccine Products S&H Summaries

6 Months Through 5 Years of Age
Moderna COVID-19 Vaccine
Storage and Handling Summary

Basics

- Store vaccine in a freezer or refrigerator. See guidance below for each storage unit.
- Each box contains 10 multidose vials.
 - Each multidose vial contains up to 10 doses.
- Each box is approximately 2 inches by 2 inches by 5.4 inches
- Check and record storage unit temperature each workday. See guidance below for each type of temperature monitoring device. Save storage records for 3 years, unless your jurisdiction requires a longer time period.

Deliveries

Vaccine

- The vaccine will arrive frozen between -50°C and -15°C (-58°F and 5°F).
- Examine the shipment for signs of damage.
- Open the box and remove TagAlert Temperature Monitor from box (placed in the inner box next to vaccine).
- Check the TagAlert temperature monitoring device by pressing the blue "start and stop" button.
 - Left arrow points to a **green checkmark**: The vaccine is ready to use. Store the vaccine at proper temperatures immediately.
 - Right arrow points to a **red X**: The numbers 1 and/or 2 will appear in the display. Store the vaccine at proper temperatures and label **DO NOT USE!** Call the phone number indicated in the instructions or your jurisdiction's immunization program **IMMEDIATELY!**
- The expiration date is NOT printed on the vaccine vial or carton. To determine the expiration date:
 - Scan the QR code located on the outer carton, or
 - Go to www.modernatx.com/covid19vaccine-usa/.

Ancillary Supply Kit

An ancillary supplies kit will be delivered separately from the vaccine and includes:

- Administration supplies:** Needles, syringes, sterile alcohol prep pads, vaccination record cards, and some PPE.
- Ancillary supply kit(s) support the number of doses ordered.

Freezer

Unpunctured, frozen vaccine vials may be stored in the freezer between -50°C and -15°C (-58°F and 5°F).

- Store in the original carton.
- Protect from light.
- Do not store with dry ice or below -50°C (-58°F).
- Do NOT refreeze thawed vaccine.

06/19/2022 00010714

6 Months Through 4 Years of Age
Pfizer-BioNTech COVID-19 Vaccine
Storage and Handling Summary

Basics

- Store vaccine in an ultra-cold freezer or refrigerator. See guidance below for each storage unit.
- Do NOT store in:
 - The thermal shipping container*
 - A freezer
- Check and record storage unit temperatures each workday. See guidance below for each type of storage unit. Save storage records for 3 years, unless your jurisdiction requires a longer time period.

Deliveries

Vaccine

- The vaccine will arrive in a thermal shipping container at ultra-cold temperatures between -90°C and -60°C (-130°F and -76°F) with dry ice. The vial for children 6 months through 4 years of age has a maroon cap and maroon-bordered label.
- Follow the manufacturer's guidance (www.cvdvaccine-us.com/) for:
 - Unpacking the vaccine
 - Returning the temperature monitoring device
 - Disposing of the thermal shipping container.

Ancillary Supply Kit

An ancillary supply kit will be delivered separately from the vaccine and includes:

- Mixing supplies:** Diluent, needles, syringes, and sterile alcohol prep pads
 - Mixing supplies are packaged separately with a green identification label.
 - Do NOT use mixing supplies to administer vaccine.
- Administration supplies:** Needles, syringes, sterile alcohol prep pads, vaccination record cards, and some PPE.
- Ancillary supply kits support the number of doses ordered.

Ultra-Cold Freezer

Before mixing, the vaccine may be stored in an ultra-cold freezer between -90°C and -60°C (-130°F and -76°F).

- Store vaccine vials upright in the tray or box.
- Protect from light.
- Vaccine may be stored until the expiration date. Vaccine expires 12 months after the manufacture date.
 - The manufacture date is printed on the vial.
 - Count out 12 months, using the month printed on the vial as month 1.
- The vaccine expires on the last day of the 12th month
- Expired vaccine should NEVER be administered. To prevent this, use CDC's COVID-19 Vaccine Expiration Date Tracking Tool
- As the expiration date approaches, contact the manufacturer to determine if it has been extended. Do not discard vaccine without ensuring the expiration date has passed.

Month 1: Jan 2022 (Printed on vial)

Month 3: March 2022

Month 6: June 2022

Month 9: Sept 2022

Month 12: Dec 2022 Expires Dec 31, 2022

06/18/2022 00001070-6K



Vaccinate
ALL 58

Moderna Infant/Toddler (6mos-5yrs) S&H Summary

Pfizer Infant/Toddler (6mos-4yrs) S&H Summary



Moderna Inclusive Storage and Handling Summary

Ages: 6 Months and Older
Moderna COVID-19 Vaccine Products
Storage and Handling Summary

Information applies to Moderna COVID-19 vaccine products including those for persons ages:

- 6 months through 5 years (blue capped vial with magenta-bordered label)
- 6 years through 11 years of age (blue capped vial with purple-bordered label)
- 12 years of age and older (red capped vial with blue-bordered label)

Basics

- Store vaccine in a purpose-built refrigerator or freezer.
- Use a digital data logger to monitor temperature of the storage unit.
- Check and record storage unit temperatures daily.

Deliveries

The vaccine will arrive frozen between -50°C and -15°C (-58°F and 5°F).

Unpack vaccine immediately upon arrival at the clinic.

- Check the cold chain monitor (CCM), a device used to monitor vaccine temperatures during transport (if one was included) for any indication of a temperature excursion during transit.

Check the expiration date by scanning the QR code on the outer carton or go to www.modernatx.com/covid19vaccine-usa/.

Ancillary supplies including needles, syringes, vaccination record

Storing Vaccine

Freezer storage between -50°C and -15°C (-58°F and 5°F) until the expiration date.

- Unpunctured, frozen vaccine vials may be stored in the freezer.
 - Do NOT** refreeze thawed vaccine
- Store in the original carton.
- Protect from light.
- Do not store with dry ice or below -50°C (-58°F).

Refrigerator storage between 2°C to 8°C (36°F to 46°F) for up to 30 days.*

- Monitor how long the vaccine has been in the refrigerator using CDC's beyond-use date (BUD) labels.
 - Do NOT** use vaccine after the 30-day BUD
- Complete the information on the beyond-use date label when removing vaccine from the freezer.
- Attach the label to the box holding the vaccine vials.
- Check the BUD before administering vaccine. Do NOT use vaccine after the 30-day BUD.
- Thawed vaccine can be handled in room light.

* Unpunctured vials may be stored between 8°C to 25°C (46°F to 77°F) for a total of 24 hours.

06/23/2022 03031071-4

6 Months Through 5 Years of Age
Moderna COVID-19 Vaccine

Store vaccine between 2°C and 8°C (36°F and 46°F) for up to 30 days.

Lot number(s): 123456A

Today's date: 06/01/2022 USE BY* Date: 07/01/2022

*After this date/time, do NOT use. Contact the manufacturer for guidance. If directed to discard the vaccine, follow the manufacturer's and your jurisdiction's guidance on proper disposal.

Vaccine may be transported for 12 cumulative hours.

Transport date	6/5/22
Time in transport	2 hrs
Time remaining	10 hrs

Name: Amy Nurse RN

www.cdc.gov/vaccines/covid-19/info-by-product/moderna/storage.html

Moderna COVID-19 Vaccine Products Storage and Handling Summary for Ages 6 Months and Older



Job Aid: Preventing Administration Errors

Preventing Administration Errors

California COVID-19 Vaccination Program

Once an error or deviation has occurred, use this guidance to prevent the administration error from occurring again. Refer to CDC's [Interim Clinical Considerations](#) or [Revaccination Guidance](#) for next steps.

An administration error is any preventable event that may cause or lead to improper use of vaccine or patient harm. To reduce errors, complete [COVID-19 vaccine product training](#) and demonstrate competency for products your site will administer. Report errors to [VAERS](#) and [ISMP](#) to help prevent future errors.

Error Type	Guidance to Prevent Administration Errors
Wrong Site or Route	<p>Administer COVID-19 vaccines in deltoid muscle (or anterolateral thigh) using IM injection.</p> <ul style="list-style-type: none">If multiple vaccines are administered at a single visit, administer each injection in a different injection site. Post this anatomical illustration to help identify recommended injection sites.For people ≥11 years, the deltoid muscle can be used for more than one intramuscular injection administered at different sites in the muscle.For children (5–10 years), if more than two vaccines are injected in a single limb, the vastus lateralis muscle of the anterolateral thigh is the preferred site because of greater muscle mass.For 6 months through 2 years: The injection site is the vastus lateralis in the anterolateral thigh.For 3 years and older: The injection site is the deltoid muscle.An IM injection given with too short a needle is functionally a subcutaneous injection; post this reference guide and use clinical judgment to adjust needle length for patient weight and gender.COVID-19 vaccines may be administered without regard to timing of other vaccines. If coadministering COVID-19 vaccine with routine vaccines, prepare and organize syringes to ensure products are administered in correct site and route.Ask patient to completely expose their shoulder when administering in the deltoid muscle. Ensure vaccinators can locate upper/lower borders of a safe IM injection zone. Incorrect administration into shoulder joint instead of deltoid muscle can trigger inflammation and injury.*
Wrong Age	<p>Do not administer vaccine to an unauthorized age group.</p> <ul style="list-style-type: none">Select the correct vaccine product based on patient eligibility and age at date of vaccination.
Wrong Formulation	<p>Select correct vaccine formulation based on patient age at date of vaccination.</p> <ul style="list-style-type: none">COVID-19 vaccine dosages are based on patient age—not size or weight; administering the wrong formulation may result in a lower-than-authorized dosage and insufficient protection.Double check vial label; always verify patient birthdate. (Early shipments of Pfizer 6M-4Y do not correctly state the age indicators. Please refer to the Pfizer Provider Letter.)Refer to COVID-19 Vaccine Product Guide for cap colors and age indicators by product.
Overdosage	<p>Do not administer a higher-than-authorized vaccine injection volume for primary series and additional or booster doses.</p> <ul style="list-style-type: none">If too much vaccine is administered, dose may invoke stronger adverse effects; double check injection volume for product & dose before administration. (Report adverse events to VAERS.)

California COVID-19 Vaccination Program

IMM-1410 (6/21/22)

Preventing Administration Errors includes:

- Revaccination Guidance
- Error Types
- VAERS (Vaccine Adverse Event Reporting System)
- ISMP (Institute for Safe Medication Practices)
- Reporting
- Top 10 Errors Related to COVID-19 Vaccination



Job Aid: Reporting Inventory to VaccineFinder

COVID Locating Health
POWERED BY Castlight

COVID-19 Vaccines Other Vaccines Public Display Need Help?

[← Back to Inventory](#)

Add Vaccines to Your Inventory

Any vaccines you add to your inventory will appear automatically in your most recent .csv file as well as on your manual dashboard.

1. Choose vaccines to add (select all that apply):

☐ Select all vaccines

☐ Moderna, COVID-19 Vaccine, 100mcg/0.5mL 10 dose
(Moderna 12Y+ red cap)

☐ Janssen, COVID-19 Vaccine, 0.5 mL

☐ Pfizer-BioNTech, COVID-19 Vaccine, 10 mcg/0.2 mL, tris-sucrose
(Pfizer 5-11Y orange cap)

☐ Pfizer-BioNTech, COVID-19 Vaccine, 30 mcg/0.3mL
(Pfizer 12Y+ purple cap)

☐ Pfizer-BioNTech, COVID-19 Vaccine, 30 mcg/0.3mL, tris-sucrose
(Pfizer 12Y+ gray cap)

☐ Pfizer-BioNTech, COVID-19 Vaccine, 3 mcg/0.2 mL, tris-sucrose
(Pfizer 6M-4Y maroon cap)

☐ Moderna, COVID-19 pediatric vaccine, 25mcg/25 ml
(Moderna 6M-5Y dark blue cap)

2. Choose locations where you'd like to add your selected vaccines (select all that apply):

☐ Select all locations

☐ Your Clinic Name
Your address

[Cancel](#) [Add Vaccines](#)

Begin reporting Infant/Toddler inventory once vaccines arrive, at least weekly on Fridays by close of business.

Maximum Inventory Quantities

Report these maximum quantities to VaccineFinder for unpunctured vials:

	Pfizer 6M-4Y (Maroon cap)	Pfizer 5-11Y (Orange cap)	Pfizer 12Y+ (Gray cap)	Pfizer 12Y+ (Purple cap)	Moderna 6M-5Y (MAGENTA BORDER)	Moderna 6-11Y (PURPLE BORDER)	Moderna 12Y+ (Red cap)	Janssen (Light blue cap)
NDC (Unit of Use)	59267-0078-01	59267-1055-01	59267-1025-01	59267-1000-01	80777-279-05	80777-275-05	80777-273-10	59676-580-05
Max Doses Reported (unpunctured)	10	10	6	6	10	5	10	5

Vaccine Management

Eric Norton, My Turn, and Maria Volk, CDPH

Infant/Toddler Standard Reports – Went Live on June 29th



Two new standard reports: **Infant/Toddler Appointments by Dose & Brand** and **Infant/Toddler Appointments by Patient** went live in Release 28.3 on June 29th.

The current Standard Reports have the following changes:

- The Dose field has been updated to pick up Infant/Toddler Pfizer & Moderna records.
- The existing “Dose” filter can filter for Infant/Toddler Pfizer & Moderna records.

Moderna 6-17 My Turn Workaround



Prior to Release 28.4 on July 7th



Please use the Bulk Walk-In Upload functionality!

In My Turn, you **can now** input vaccination appointments for Moderna in the 6-17 age group using the Inline Bulk Upload functionality, as well as using the CSV file on the Bulk Walk-In Upload tab in My Turn.

Release 28.4 – Coming July 7th



As a part of Release 28.4 on July 7th:



Moderna **6-17 Scheduling** will be enabled in My Turn.



A “Back” button will be added to the ineligible registration page. This will ensure that the users don’t have to start over while scheduling appointments if they enter incorrect information.

Live Support Schedule – July 4th



My Turn and
myCAvax Help Desk



Closed Operation

- July 4th

COVID-19 Provider
Call Center



Closed Operation

- July 4th

Support will resume on Tuesday, July 5th

myCAvax Delivery Cadence for Week of July 4th



Providers should submit vaccine orders on or *before* the regular order deadline of Monday, July 4 at 5 PM. The deadline will not change due to the holiday.



McKesson shipments will **not** be delivered Monday, July 4 through Tuesday, July 5.

Deliveries will resume Wednesday, July 6.

Pfizer shipments will **not** be delivered Monday, July 4.

Deliveries will resume Tuesday, July 5.

TPR (AmerisourceBergen) shipments will **not** be delivered Monday, July 4 through Tuesday, July 5.

Deliveries will resume Wednesday, July 6.

myCAvax Moderna (ages 6-11) Product Ordering






On Thursday, June 23rd the ACIP recommended the FDA's EUA amendment to include Moderna's 6-17 products.

The 12–17-year-old group will receive the same product as 18 and older populations. This product is currently available for ordering in myCAvax. The product has been renamed in myCAvax to include the full age group.

The Moderna formulation for the 6-11 group was added in myCAvax on June 24th. Ordering began on June 27th.

APPENDIX

Slide Icon Key

Icon	Meaning
	This is to label slides that are referencing upcoming or existing functionality and how to use it in the system.
	This is to label slides that include important system reminders.
	This is to label slides that include tips and best practices to improve your system experience.

myCAvax Release Roadmap

RECENTLY DEPLOYED

June 16th (R27.0)

Orders

- ✓ LHDs to Move Small Orders to Standard Orders
- ✓ Order Page Layout Changes
- ✓ New order cancelation 'Status Reason' options
- ✓ Update Audit History for Orders/Transfers
- ✓ Add 'Doses Requested' to Standard Order Screen

Account

- ✓ Storing DocuSign at the Location Application

Community

- ✓ Add Knowledge Center article to account page
- ✓ Change Flow Title for Multiple Flows

Other

- ✓ Auto-Deactivate Licenses
- ✓ Default tab display on opening of records
- ✓ Remaining email templates to Lightning

IN PROGRESS

July 14th (R28.0)

Orders

- ✓ Order Fulfillment Updates to allow multiple lots and general UI enhancements
- ✓ Allow CDPH and LHD users to update additional details on the Shipment Records such as quantity, product, expiration date, etc.
- ✓ Validate Shipping Hours
- ✓ Set Flags for Temporary Closure on Vaccine Order Review page

Account

- ✓ Temporary Closure for Location Accounts
- ✓ Add VFC Regions to Accounts
- ✓ Add Calibration Expiration date to Storage Unit List

Community

- ✓ Update Thermometer Type options
- ✓ Add Data Logger as Shipment Incident Type

Site Visits

- ✓ Provider Category
- ✓ VFC Assigned Pin

Other

- ✓ Put LHD Dashboard on LHD Homepage

UPCOMING

August 11th (R29.0)

Orders

- ✓ Draft Order Enhancements

Account

- ✓ Provider initiated Disenrollment
- ✓ Disenrollment due to inactivity

Other

- ✓ Start of Contact enhancements to remove duplicate contacts
- ✓ Sharing Rule enhancements for accounts, storage units, etc.

My Turn Public Product Roadmap

RECENTLY DEPLOYED

June 20th (R27)

Release 28

- ✓ Pfizer Infant/Toddler rollout for 3 dose primary series for children 6 months-4-years old
- ✓ Moderna Infant/Toddler rollout for 2 dose primary series for children 6 months-5-years old
- ✓ [Testing] Update error messaging for better user experience and accessibility
- ✓ [Continued] Failure Point Notification – setting up monitoring tools throughout system to flag (potential) issues
- ✓ Continued Analysis – Consider Walk-in and bulk upload appointments for clinic's Public Portal capacity and availability

CURRENT

July 7th (R28.4)

Release 28.4

- ✓ Moderna 6-11 and 12-17 rollout
- ✓ [Testing] Update error messaging for better user experience and accessibility
- ✓ [Continued] Failure Point Notification – setting up monitoring tools throughout system to flag (potential) issues
- ✓ Continued Analysis – Consider Walk-in and bulk upload appointments for clinic's Public Portal capacity and availability

UPCOMING

July 27th (R29)

Release 29

- ✓ Removing flu – zero out flu vaccine supplies to remove nasal spray and flu shot tags
- ✓ In-home vaccination and transportation page updates to reflect guidance for under 5 patients
- ✓ [Testing] Custom flows for vaccine type
- ✓ [Delivery] Update error messaging for better user experience and accessibility
- ✓ [Continued] Failure Point Notification – setting up monitoring tools throughout system to flag (potential) issues
- ✓ [Testing] Consider Walk-in and bulk upload appointments for clinic's Public Portal capacity and availability

My Turn Clinic Product Roadmap

RECENTLY DEPLOYED

June 20th (R28)

Release 28

- ✓ Moderna Infant/Toddler 6 month-5-years two dose series
- ✓ Pfizer Infant/Toddler 6 month-4-years three dose series
 - ✓ Dose Fields Update
 - ✓ Add Vaccine Supply & Inventory
 - ✓ Bulk Walk-In Upload
 - ✓ Clinic Creation Setup
 - ✓ Walk-in Flow Update
 - ✓ Vaccine Administrator Flow Update
 - ✓ Single/Bulk Update
 - ✓ Appointment/IIS Tab Filter Update
 - ✓ Dashboard Homepage Update

CURRENT

July 7th (R28.4)

Release 28.4

- ✓ Moderna 6-years-11-years two dose series
- ✓ Moderna 12-years-17-years two dose series
 - ✓ Add Vaccine Supply & Inventory
 - ✓ Bulk Walk-In Upload
 - ✓ Clinic Creation Setup
 - ✓ Walk-in Flow Update
 - ✓ Vaccine Administrator Flow Update
 - ✓ Single/Bulk Update
 - ✓ Appointment/IIS Tab Filter Update
 - ✓ Dashboard Homepage Update

UPCOMING

July 27th (R29)

Release 29

- ✓ [SMS/Email] Opt-out on the Walk-In flow
- ✓ [Vaccine Inventory] Entering Lot Numbers correctly
- ✓ [CAIR2] Concatenate "Cross Street 1" and "Cross Street 2"

Wrap-up

Leslie Amani, CDPH

Additional Support

Type of Support

Description

Updated 6.6.22



COVID-19 Provider Call Center

The COVID-19 Call Center for Providers and Local Health Departments is dedicated to medical providers in California and their COVID-19 response, specifically addressing questions about State program requirements, enrollment, and vaccine distribution, including the Vaccine Marketplace.


- Email: covidcallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–6PM



Enrollment Support

For Provider enrollment support, please contact myCAvax Clinic Operations at

- Email: myCAvaxinfo@cdph.ca.gov




myCAvax Help Desk

Dedicated staff provide up-to-date information and technical support on the myCAvax system.

- Email: myCAvax.HD@Accenture.com
- Phone: (833)-502-1245, option 3, Monday through Friday 8AM–6PM


For training opportunities: <https://eziz.org/covid/education/>



My Turn Clinic Help Desk

For **onboarding support** (those in the process of onboarding): myturnonboarding@cdph.ca.gov
For **technical support** with My Turn Clinic for COVID-19 and flu vaccines: MyTurn.Clinic.HD@Accenture.com or (833) 502-1245, option 4: Monday through Friday 8AM–6PM

For job aids, demos, and training opportunities: flu at <https://eziz.org/covid/myturn/flu/> and COVID at <https://eziz.org/covid/myturn/>



Archived Communications

For archived communications from the COVID-19 Provider Call Center about the California COVID-19 Vaccination Program visit

- Website: [EZIZ Archived Communications](#)


Public COVID-19 Call Center

- Phone: (833) 422-4255: M-F 8AM-8PM; S-S 9AM-5PM
- For questions about general COVID questions, including COVID-19 vaccines, scheduling vaccination appointments through My Turn, school-related question, masking, testing, and more.



Provider Office Hours Q&A

During today's session, please use the Q&A panel to ask your questions so our subject matter experts can respond directly.



Thank you!



Monday

My Turn and myCAvax Office Hours

Next session: Monday, July 11, 12PM

Canceled for July 4th Holiday



Friday

Provider Office Hours

Next session: Friday, July 8, 9AM



Vaccinate
ALL 58

Thank you to Provider Office Hours' Planning Team: Leslie Amani, Cecilia LaVu, Blanca Corona, Charles Roberts, Hailey Ahmed, & Samantha Sears.